Pimavanserin + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Adjunctive Treatment of Major Depressive Disorder

Conditions

Adjunctive Treatment of Major Depressive Disorder

Trial Timeline

Apr 25, 2019 → May 29, 2020

NCT ID

NCT03968159

About Pimavanserin + Placebo

Pimavanserin + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Adjunctive Treatment of Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03968159. Target conditions include Adjunctive Treatment of Major Depressive Disorder.

What happened to similar drugs?

0 of 1 similar drugs in Adjunctive Treatment of Major Depressive Disorder were approved

Approved (0) Terminated (1) Active (0)

❌PimavanserinAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05523895	Phase 2/3	Completed	Aug 9, 2022	Sep 27, 2024	Irritability Associated With Autism Spectrum Disorder
NCT04531982	Phase 3	Completed	Aug 5, 2020	Feb 19, 2024	Schizophrenia
NCT03968159	Phase 3	Completed	Apr 25, 2019	May 29, 2020	Adjunctive Treatment of Major Depressive Disorder
NCT03575052	Phase 3	Completed	May 21, 2018	May 6, 2022	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT02970305	Phase 2	Completed	Nov 4, 2016	Oct 28, 2019	Schizophrenia
NCT02970292	Phase 3	Completed	Oct 26, 2016	Jun 25, 2019	Schizophrenia

Competing Products

2 competing products in Adjunctive Treatment of Major Depressive Disorder

See all competitors

Product	Company	Stage	Hype Score
Pimavanserin	Acadia Pharmaceuticals	Phase 2	32
Pimavanserin	Acadia Pharmaceuticals	Phase 3	29